Will FDA issue a Complete Response Letter for a novel therapeutic biologic in Q2 2026?

This market tracks whether the FDA issues a Complete Response Letter (CRL) for any novel therapeutic biologic (BLA) with a PDUFA date in Q2 2026 (April–June). A CRL must be publicly reported or confirmed via FDA filing correspondence, press releases, or regulatory databases. Withdrawals or voluntary holds do not count. tracks LONG if at least one CRL is issued; SHORT if no CRLs are issued for any novel therapeutic biologic BLA during the quarter.